Advertisement
Singapore markets close in 6 hours 18 minutes
  • Straits Times Index

    3,328.64
    +10.19 (+0.31%)
     
  • Nikkei

    38,773.64
    -126.38 (-0.32%)
     
  • Hang Seng

    18,986.90
    +159.55 (+0.85%)
     
  • FTSE 100

    8,317.59
    -21.64 (-0.26%)
     
  • Bitcoin USD

    68,622.73
    -579.65 (-0.84%)
     
  • CMC Crypto 200

    1,490.40
    +6.21 (+0.42%)
     
  • S&P 500

    5,304.72
    +36.88 (+0.70%)
     
  • Dow

    39,069.59
    +4.29 (+0.01%)
     
  • Nasdaq

    16,920.79
    +184.79 (+1.10%)
     
  • Gold

    2,353.70
    +19.20 (+0.82%)
     
  • Crude Oil

    78.86
    +1.14 (+1.47%)
     
  • 10-Yr Bond

    4.4670
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,617.26
    -1.01 (-0.06%)
     
  • Jakarta Composite Index

    7,285.36
    +108.94 (+1.52%)
     
  • PSE Index

    6,527.55
    -44.05 (-0.67%)
     

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB
dan@1abmedia.com